Spravato®
What is Spravato®?
SPRAVATO® is a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist. It is the only FDA approved esketamine nasal spray. For more information click here.
What is Spravato® indicated for?
SPRAVATO® is indicated and prescribed for
Treatment-resistant depression (TRD) in adults, as monotherapy or in conjunction with an oral antidepressant.
Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.
What does treatment look like?
Treatment is patient administered under the supervision of a healthcare professional. Dosing frequency typically is twice a week for 4 weeks, once a week for 4 weeks, and potentially every two weeks there after.
At Charis Psychiatry, treatments will be in office and require two hours of monitoring. Transportation by a family member or friend is required due to potential side effects or sedation, dissociation, respiratory depression.
Below is where treatments will occur in order to provide a therapeutic, comfortable, and safe environment.
Can I still take my antidepressant?
Yes! SPRAVATO® can be prescribed as monotherapy or in conjunction with your antidepressant. If you already have a provider for medication management, I would coordinate care closely before and during treatment.
As a therapist or provider, how can I refer patients to you for SPRAVATO® treatment?
Please click here for the referral form.